Hiv treatment as prevention: Models, data, and questions-towards evidence-based decision-making

The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group

doi:10.1371/journal.pmed.1001259

Hiv treatment as prevention: Models, data, and questions-towards evidence-based decision-making

The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group

Research output: Contribution to journal › Article › peer-review

Abstract

Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.

Original language	English
Article number	e1001259
Journal	PLoS Medicine
Volume	9
Issue number	7
DOIs	https://doi.org/10.1371/journal.pmed.1001259
State	Published - 1 Jul 2012
Externally published	Yes

Bibliographical note

Funding Information:
GG is currently employed by the Bill & Melinda Gates Foundation. In the past 5 yeas GG has received grants from the Wellcome Trust, Medical Research Council the Gates Foundation and UNAIDS. In the past 5 years GG has been a consultant for GSK and Merck working on HPV vaccination and for Viropharma to work on stem cell transplantation. CM is employed by a commercial company that provide consulting services in health economics to pharmaceutical companies and donor organizations. Much of our work is focussed on HIV/AIDS and we have been involved in projects that evaluated the health economic impact of ARV treatment for prevention. The company was, however, not compensated for being part of the HIV modeling group that wrote this article. WM receives US NIH grant support. JS is a member of the PLoS Medicine Editorial Board. BZ is PI of the ALPHA network of HIV community-based cohort studies that may supply data to the modelling consortium. All other authors have declared that no competing interests exist. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the agencies represented, including US Centers for Disease Control and Prevention (CDC), PEPFAR, UNAIDS, WHO, or the Bill & Melinda Gates Foundation.

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1371/journal.pmed.1001259

Cite this

@article{ba263fd53abe44a7aef193edcd445ba5,

title = "Hiv treatment as prevention: Models, data, and questions-towards evidence-based decision-making",

abstract = "Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.",

author = "{The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group} and Till B{\"a}rnighausen and Stephen Becker and Eran Bendavid and Anna Bershteyn and John Blandford and Boily, {Marie Claude} and David Burns and Valentina Cambiano and Cohen, {Myron S.} and {\'I}de Cremin and Wim Delva and Christopher Dye and Eaton, {Jeffrey W.} and Matthias Egger and Christophe Fraser and Noya Galai and Geoff Garnett and Ghys, {Peter D.} and Hallett, {Timothy B.} and Laura Heaton and Holmes, {Charles B.} and Jan Hontelez and Britta Jewell and Olivia Keiser and Daniel Klein and Viviane Lima and Elisa Long and Rob Lyerla and Christiaan Marais and Fei Meng and Gesine Meyer-Rath and Miller, {William C.} and Nicholas Muraguri and Nichols, {Brooke E.} and Nigmatulina, {Karima R.} and Mead Over and Nancy Padian and Andrew Phillips and Carel Pretorius and Christine Rousseau and Joshua Salomon and Nalinee Sangrujee and David Serwadda and Frank Tanser and Vesga, {Juan F.} and Peter Vickerman and Damian Walker and Rui Wang and Alex Welte and White, {Richard G.}",

note = "Funding Information: GG is currently employed by the Bill & Melinda Gates Foundation. In the past 5 yeas GG has received grants from the Wellcome Trust, Medical Research Council the Gates Foundation and UNAIDS. In the past 5 years GG has been a consultant for GSK and Merck working on HPV vaccination and for Viropharma to work on stem cell transplantation. CM is employed by a commercial company that provide consulting services in health economics to pharmaceutical companies and donor organizations. Much of our work is focussed on HIV/AIDS and we have been involved in projects that evaluated the health economic impact of ARV treatment for prevention. The company was, however, not compensated for being part of the HIV modeling group that wrote this article. WM receives US NIH grant support. JS is a member of the PLoS Medicine Editorial Board. BZ is PI of the ALPHA network of HIV community-based cohort studies that may supply data to the modelling consortium. All other authors have declared that no competing interests exist. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the agencies represented, including US Centers for Disease Control and Prevention (CDC), PEPFAR, UNAIDS, WHO, or the Bill & Melinda Gates Foundation. ",

year = "2012",

month = jul,

day = "1",

doi = "10.1371/journal.pmed.1001259",

language = "English",

volume = "9",

journal = "PLoS Medicine",

issn = "1549-1277",

publisher = "Public Library of Science",

number = "7",

}

TY - JOUR

T1 - Hiv treatment as prevention

T2 - Models, data, and questions-towards evidence-based decision-making

AU - The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group

AU - Bärnighausen, Till

AU - Becker, Stephen

AU - Bendavid, Eran

AU - Bershteyn, Anna

AU - Blandford, John

AU - Boily, Marie Claude

AU - Burns, David

AU - Cambiano, Valentina

AU - Cohen, Myron S.

AU - Cremin, Íde

AU - Delva, Wim

AU - Dye, Christopher

AU - Eaton, Jeffrey W.

AU - Egger, Matthias

AU - Fraser, Christophe

AU - Galai, Noya

AU - Garnett, Geoff

AU - Ghys, Peter D.

AU - Hallett, Timothy B.

AU - Heaton, Laura

AU - Holmes, Charles B.

AU - Hontelez, Jan

AU - Jewell, Britta

AU - Keiser, Olivia

AU - Klein, Daniel

AU - Lima, Viviane

AU - Long, Elisa

AU - Lyerla, Rob

AU - Marais, Christiaan

AU - Meng, Fei

AU - Meyer-Rath, Gesine

AU - Miller, William C.

AU - Muraguri, Nicholas

AU - Nichols, Brooke E.

AU - Nigmatulina, Karima R.

AU - Over, Mead

AU - Padian, Nancy

AU - Phillips, Andrew

AU - Pretorius, Carel

AU - Rousseau, Christine

AU - Salomon, Joshua

AU - Sangrujee, Nalinee

AU - Serwadda, David

AU - Tanser, Frank

AU - Vesga, Juan F.

AU - Vickerman, Peter

AU - Walker, Damian

AU - Wang, Rui

AU - Welte, Alex

AU - White, Richard G.

N1 - Funding Information: GG is currently employed by the Bill & Melinda Gates Foundation. In the past 5 yeas GG has received grants from the Wellcome Trust, Medical Research Council the Gates Foundation and UNAIDS. In the past 5 years GG has been a consultant for GSK and Merck working on HPV vaccination and for Viropharma to work on stem cell transplantation. CM is employed by a commercial company that provide consulting services in health economics to pharmaceutical companies and donor organizations. Much of our work is focussed on HIV/AIDS and we have been involved in projects that evaluated the health economic impact of ARV treatment for prevention. The company was, however, not compensated for being part of the HIV modeling group that wrote this article. WM receives US NIH grant support. JS is a member of the PLoS Medicine Editorial Board. BZ is PI of the ALPHA network of HIV community-based cohort studies that may supply data to the modelling consortium. All other authors have declared that no competing interests exist. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the agencies represented, including US Centers for Disease Control and Prevention (CDC), PEPFAR, UNAIDS, WHO, or the Bill & Melinda Gates Foundation.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.

AB - Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.

UR - http://www.scopus.com/inward/record.url?scp=85032293737&partnerID=8YFLogxK

U2 - 10.1371/journal.pmed.1001259

DO - 10.1371/journal.pmed.1001259

M3 - Article

C2 - 22802739

AN - SCOPUS:85032293737

SN - 1549-1277

VL - 9

JO - PLoS Medicine

JF - PLoS Medicine

IS - 7

M1 - e1001259

ER -

Hiv treatment as prevention: Models, data, and questions-towards evidence-based decision-making

Abstract

Bibliographical note

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this